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Prostaglandins are important mediators of the body’s
response to pain and inflammation, and are formed from
essential fatty acids found in cell membranes. This
reaction is catalysed by cyclooxygenase, a membrane-
associated enzyme occurring in two isoforms, COX-1
and COX-2. Non-steroidal anti-inflammatory drugs
(NSAIDs) act by inhibiting the activity of COX. The
investigation of Eucomis species (a popular South
African medicinal plant) for potential anti-inflammatory
activity showed high levels of COX-1 and -2 inhibitory
activity associated with several species, specifically E.
autumnalis and E. humilis. Further investigation was
conducted using E. autumnalis subspecies autumnalis,
as this is the species that is most widely utilised by tra-
ditional healers in southern Africa. The bulb extracts
from this species were characterised by higher IC50 val-
ues for both COX-1 and COX-2 inhibition than obtained
for the leaf and root extracts. The ratio of COX-2/COX-1
inhibitory activity was, however, similar to that of the
root extracts, both values being less than one. The leaf
extracts showed higher COX-1 than COX-2 inhibitory
activity, with a ratio of 1.9. Most traditional remedies util-
ising Eucomis, are prepared from the bulbs (possibly
including some root material) of this species.
Inflammatory and related immune responses are normal
defence mechanisms essential to health. These responses
are, however, potentially harmful and play a major role in
diseases such as rheumatoid arthritis and asthma (Hinman
1973). Inflammation is a complex process with many differ-
ent mediators, including prostaglandins (Campbell 1990).
The inflammatory response involves enzyme activation,
mediator release, extravasation of fluid (oedema), cell
migration, tissue breakdown and repair (Vane and Botting
1995).
Prostaglandins and related eicosanoids (thromboxanes
and leucotrienes) are a family of pharmacologically active,
acidic lipids produced from cell membranes (Smith 1990).
Eicosanoid precursors (usually arachidonic acid) are trans-
formed by one of two pathways in the body, catalysed by
either prostaglandin endoperoxide sythetase or the lipoxge-
nases (Smith 1990). The synthesis of prostaglandins is a
key factor in inflammation and pain. The primary enzyme
responsible for prostaglandin synthesis is cyclooxygenase
(Wallace and Chin 1997), and this enzyme controls the rate-
limiting step in arachidonate metabolism (Taketo 1998). The
prostaglandin synthetase enzyme complex (cyclooxyge-
nase) is ubiquitous, with activity varying with tissue type, and
exhibits both cyclooxygenase and peroxidase activity (Smith
1990).
The cyclooxygenase enzyme occurs in two isoforms,
COX-1 and COX-2 (Goetzl et al. 1995). The constitutively
expressed COX-1 is present in cells under physiological
conditions and produces protective substances for the stom-
ach and kidney. COX-1 is responsible for the production of
prostanoids that maintain mucosal blood flow, promote
mucous secretion, inhibit neutrophil adherence and maintain
renal blood flow (Wallace and Chin 1997). Suppression of
COX-1 results in adverse side-effects including a reduction
in mucosal blood flow and mucous secretion, delay in the
healing of ulcers and a reduction in renal blood flow
(Wallace and Chin 1997). In contrast to COX-1, COX-2 is
effectively absent in healthy tissue and is induced in migra-
tory and other cells by proinflammatory agents, such as
cytokines, mitogens and endotoxins under pathological con-
ditions such as inflammation (Mitchell et al. 1994). Both
enzymes have similar active sites, although the active site of
the COX-2 enzyme is thought to be larger than that of COX-
1. This is suggested by the broader fatty acid substrate
specificity of COX-2 and the lower relative affinities of
NSAIDs for COX-2 (Taketo 1998). With the onset of inflam-
mation or tissue damage, levels of COX-2 increase sub-
stantially (Vane and Botting 1995). Prostanoids produced by
COX-2 promote oedema, fever and pain (Wallace and Chin
1997).
Non-steroidal anti-inflammatory drugs (NSAIDs) are a
large, chemically diverse group of drugs that act by inhibit-
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ing the activity of COX (Vane and Botting 1995). This
explains both their effectiveness (in the inhibition of COX-2)
and their side effects, manifest in gastrointestinal bleeding
and perforation and renal damage (in the inhibition of COX-
1) (Mitchell et al. 1994).
Aspirin, indomethacin and ibuprofen have been found to
be more potent inhibitors of COX-1 than COX-2 in several
model test systems. The relative potencies of aspirin and
indomethacin vary slightly between models although the IC50
values are different (Mitchell et al. 1994). Research has, for
the past fifty years, focused on the development of NSAIDs
that show reduced toxicity in the gastrointestinal tract and
kidney. This is complicated by the mechanistic link between
the beneficial and adverse effects of NSAIDs, both of which
relate to the ability of the drug to inhibit prostaglandin syn-
thesis (Wallace and Chin 1997). The aim is to develop high-
ly selective COX-2 inhibitors which cause less gastrointesti-
nal damage. A limited number of selective COX-2 inhibitors
of natural origin have been isolated (Noreen et al. 1998).
Investigation of plant extracts in terms of COX-2 inhibition is
thus of primary importance, considering the potential value
of such compounds.
Plants have been selected and used empirically as drugs
for centuries, initially as traditional preparations then as pure
active principles (Kamil 1993). Natural products and their
derivatives represent more than 50% of all the drugs in clin-
ical use today with 25% originating from higher plants
(Balandrin et al. 1993). The estimated 500 000 higher plant
species known thus form a vast potential pool for the further
investigation and exploration of plant products for future use
in medicine. Furthermore, the ethnobotanical approach to
drug discovery shows great potential for the discovery of
new drugs in the fields of dermatological, inflammatory and
gastrointestinal illnesses, as these are the most commonly
treated ailments in developing countries (Cotton 1996).
Testing extracts prepared from widely utilised medicinal
plants has become a rapidly growing and successful field in
pharmacological science.
Eucomis L’Herit (Family Hyacinthaceae) are deciduous
geophytes with long, narrow leaves and erect, densely
packed flower spikes (Baker 1897, Compton 1990). The
bulbs are popular in traditional medicine for the treatment of
a variety of ailments, commonly those with underlying symp-
toms of pain and inflammation (Hutchings et al. 1996, Van
Wyk et al. 1997). An initial screening of the different species
for COX-1 and COX-2 inhibitory activity was conducted
using the bulb extracts (ethanol). The investigation then
focussed on the study of the anti-inflammatory activity (both
COX-1 and -2) of plant extracts prepared from the leaves,
bulbs and roots, of the heavily utilised species Eucomis
autumnalis Mill. (Chitt) (subspecies autumnalis) (Reyneke
1980). In this study, the relative inhibitory effects of different
extracts on the activities of purified cyclooxygenase enzyme
preparations (COX-1 in sheep seminal vesicles, COX-2 in
sheep placenta) were assessed. Eucomis autumnalis
autumnalis was chosen as the test species due to its avail-
ability and the widely reported usage of the bulbs in tradi-
tional medicine from the Zulu, Xhosa and Sotho cultures.
Materials and Methods
Plant material
Leaf, bulb and root material was obtained from specimens of
Eucomis growing in the Botany Department Garden green-
houses (University of Natal, Pietermaritzburg). Voucher
specimens (Taylor01-11) were prepared and submitted to
the University of Natal Herbarium. Harvested material (sum-
mer) was divided into leaves, bulbs and roots. The plant
material was cut up, placed in paper bags and dried at 50°C
for three days. Dried material was finely ground and extract-
ed in a sonication bath (for the crude ethanol extract) or
using a Soxhlet apparatus (serial extraction). Extracts were
filtered through Whatman No. 1 filter paper and dried under
vacuum at 35°C. The residue was resuspended in the
extracting solvent at 10mg ml-1.
Determination of IC50 values
A dilution series was prepared for the calculation of the IC50
values of the extracts. These were calculated by regression
analysis of the results for four different concentrations of the
sample. The IC50 value for indomethacin was determined to
be 3.1μM for the COX-1 assay and 188μM for the COX-2
assay, giving a COX-2/COX-1 ratio of 61. This correlates
well with the value of 60 recorded in the literature (Vane and
Botting 1995, Taketo 1998).
Serial extraction (Soxhlet)
Dried ground plant material (10g) was placed in a thimble
and covered with glass wool. The solvent (150ml) was heat-
ed to boiling and maintained for 2.5h. The extraction solution
was filtered through Whatman No. 1 filter paper and dried
under vacuum at 35°C. The residue was weighed and resus-
pended at 10mg ml-1 (a concentration of 250μg ml-1 in the
assay) This procedure was followed for the solvents hexane,
ethyl acetate and ethanol.
Enzyme assays
The basic protocol for the COX-1 and COX-2 assays is the
same, allowing a comparison of the inhibitory effects of the
extracts on the two enzymes.
The COX-1 assay was performed according to White and
Glassman (1974), modified by Jäger et al. (1996). The COX-
1 enzyme was prepared from sheep seminal vesicles
homogenised in potassium phosphate buffer with 1mM
EDTA (on ice). The homogenate was centrifuged and the
cell debris discarded. The microsomes were isolated by cen-
trifugation of the supernatant at 100 000g for 1h. The micro-
somal pellet was resuspended in 0.1M K-Pi (pH 7.4) and the
enzyme concentration determined by a standard protein
assay. Standardised aliquots were stored at -70°C.
Ten microlitres of the standardised enzyme preparation,
and 50μl of co-factor solution (per sample) were preincubat-
ed for 15min on ice. This solution (60μl) was added to the
test solution (2.5μl plant extract + 17.5μl water) and prein-
cubated for 5min at room temperature. 14C-Arachidonic acid
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(20μl) was added to this enzyme-extract mixture and incu-
bated for exactly 8 min in a water bath at 37°C. The reaction
was terminated with 10μl 2N HCl.
The COX-2 assay described by Noreen et al. (1998), with
minor modifications, was followed. Purified COX-2 enzyme
(isolated from sheep placental cotyledons) was purchased
from Cayman Chemicals. The enzyme (3 units) was activat-
ed with 50μl co-factor solution on ice (5min). The enzyme
solution (60μl) and sample (2.5μl ethanol extract + 17.5μl
water) were preincubated for 5min at room temperature. The
reaction was initiated with the addition of 20μl 14C-arachi-
donic acid and the solutions were incubated for exactly 10
min in a water bath at 37°C. The reaction was terminated
with 10μl 2N HCl.
Controls
In each test four controls were run (2.5μl ethanol + 17.5μl
water). Two were backgrounds in which the enzyme was
inactivated with HCl before the addition of 14C-arachidonic
acid, and which were kept on ice during the assay, and two
were solvent blanks. In addition, indomethacin standards (5
μM for the COX-1 assay and 200μM for the COX-2 assay)
were included in each test. A further standard included in the
COX-2 assays was nimesulide (200μM)
Separation of prostaglandins
Unlabelled prostaglandin carrier solution (4μl per sample)
was added to the reaction mixture and 14C-prostaglandins
synthesised in the assay were separated from the
unmetabolised arachidonic acid by column chromatography
using silica columns. Silica gel (Kieselgel 60, Korngroesse
0.063–0.200mm, 70–230 mesh ASTM) in eluent 1 was
packed to a height of 3cm in Pasteur pipettes stoppered with
glass wool. The assay mixture was applied to the column
with 1ml eluent 1. This was followed by an additional 4ml
eluent 1 to elute the unreacted arachidonic acid, which was
then discarded. The prostaglandins were then eluted into
scintillation vials using 3ml eluent 2. Scintillation fluid (4ml)
was added and the radioactivity was counted after 1h in the
dark, using a Beckman LS3801 scintillation counter.
Solutions prepared for assays
• Co-factor solution (COX-1): 0.003g L-adrenalin/ l-epineph-
rine and 0.003g reduced glutathione in 10ml 0.1 Tris
buffer, pH 8.2
• Co-factor solution (COX-2): 0.006g L-adrenalin/ l-epineph-
rine (0.9mM) and 0.003g reduced glutathione (0.49mM)
and 1μM hematin in 10ml 0.1 Tris buffer, pH 8.0
• 14C-Arachidonic acid: 16 Ci/mole, 3mM
• Prostaglandin carrier solution: 0.2mg ml-1 of unlabelled
prostaglandins (PGE2:PGF2 in the ratio 1:1)
• Eluent 1: hexane:1,4-dioxan:acetic acid (350:150:1 v/v/v)
• Eluent 2: ethyl acetate:methanol (85:15 v/v)
Calculation of inhibition
The percentage inhibition of the extracts was obtained by
measuring the amount of radioactivity in the solutions rela-
tive to that of the solvent blank (untreated sample). The
radioactivity of the control (background) was subtracted from
both the sample and the blank. Statistical analyses were
based on the results obtained from 3 different tests. One-
way ANOVA and Tukey HSD tests were performed using
Minitab Xtra (version 10.52).
Method alterations and comment
The addition of co-factors to the enzyme preparation is nec-
essary for the efficient conversion of arachidonic acid to the
prostaglandin products by COX-1 and COX-2 (Noreen et al.
1998). Reduced glutathione stimulates the biosynthesis of
prostaglandin E2 from arachidonic acid in sheep vesicular
microsomes (Raz et al. 1976). The purified protein, in the
presence of excess reducing substrate, converts arachidon-
ic acid to PGE2. In the absence of reducing substrates,
prostaglandin synthase rapidly undergoes inactivation by
low levels of hydroperoxide. This inactivation during enzy-
matic turnover is related to the peroxidase activity of the
enzyme (Markey et al. 1987). The formation of PGE2 (as well
as PGD2) increases in the presence of l-epinephrine
(Noreen et al. 1998). Since PGE2 is an important mediator of
inflammation, high yields of this prostaglandin in the control
reaction (solvent blank) increase the efficiency of the assay.
The inclusion of a pre-incubation step of the substrate and
enzyme (Zshocke pers. comm.), before the addition of the
substrate, arachidonic acid, is necessary to detect the pres-
ence of time dependent inhibitors (which include
indomethacin) of both COX-1 and COX-2 (Quellet and
Percival 1995).
Results and Discussion
A comparison of the COX-1 and COX-2 inhibitory activity
from the different Eucomis bulb extracts showed that seven
species (E. autumnalis autumnalis; E. autumnalis amaryllid-
ifolia; E. autumnalis clavata; E. humilis; E. comosa-punctata
(striata); E. comosa-punctata and E. pole-evansii) exhibited
almost equipotent COX-1 and COX-2 inhibition, while the
remaining four species (E. bicolor; E. comosa-comosa; E.
zambesiaca and the hybrid) showed higher levels of COX-1
inhibitory activity (Figure 1). High levels of anti-inflammatory
activity were associated with the extracts from E. humilis, E.
comosa-punctata (striata), E. pole-evansii, E. comosa-punc-
tata and E. autumnalis (subspecies amaryllidifolia and
autumnalis). These are among the commonly utilised medic-
inal plant species in southern Africa. This is thus a highly
significant result in terms of the pharmacological evaluation
of the genus, and provides sufficient evidence both to vali-
date the use of this plant in traditional medicine and to war-
rant further investigation into the nature of the active princi-
ple(s).
Previous studies have shown high levels of COX-1
inhibitory activity in ethanol extracts prepared from the dried
leaves, bulbs and roots (screened at 250μg ml-1) for the var-
ious Eucomis species, while aqueous extracts (screened at
500μg ml-1) showed much lower levels of activity (Taylor and
Van Staden 2001). In general, the highest levels of anti-
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inflammatory activity were observed for the ethanol bulb and
root extracts.
A study of the COX-2 inhibitory activity from the different
plant parts of E. autumnalis autumnalis (Figure 2) shows that
the crude extracts from the leaves and roots have signifi-
cantly higher activity than the bulb extracts. This suggests
that the leaves could serve as a viable and sustainable alter-
native to the more destructive use of bulb and root material,
opening up possibilities for cultivation and thus conservation
of the genus.
Dose-response curves were drawn (Figure 3) for the
crude ethanol extracts of the leaves, bulbs and roots of E.
autumnalis autumnalis for both assays. From this data, the
IC50 values were calculated by regression analysis (Table 1).
A low COX-2/COX-1 ratio indicates a preferential COX-2
inhibitor, which is valuable pharmacologically. All parts of the
plant have reported medicinal usage (Hutchings et al. 1996,
Roberts 1990), and these results further corroborate previ-
ous studies based on the COX-1 inhibitory activity (Taylor
and Van Staden 2001).
Serial extraction of the leaf, bulb and root material of E.
autumnalis autumnalis was thus conducted and the inhibito-
ry activity of these extracts compared for COX-1 and COX-
2 inhibitory activity (Figure 4).
For the leaf extracts, the COX-1 inhibitory activity was sig-
nificantly higher than that of the COX-2, with no inhibition of
the COX-2 enzyme by the ethanol fraction (Figure 4A). The
trend of higher COX-1 than COX-2 inhibition was continued
in the bulb extracts (Figure 4B), but was reversed for the root
extracts (Figure 4C). The difference between the COX-1 and
COX-2 inhibition levels in the bulb and root extracts was
much less than for the leaf extracts. This pattern of inhibition
differs from that of the crude ethanol extracts which show
higher COX-2 than COX-1 inhibition for both the bulb and
root extracts. This implies that there are different (multiple)
compounds, present in the various plant parts tested, that
are responsible for the anti-inflammatory of the respective
extracts, which leads to the different levels of anti-inflamma-
tory activity in the different solvent extracts.
The screening of plant extracts is motivated by the poten-
tial discovery of new drugs that could be developed for use
later in clinical medicine. This procedure has the potential of
uncovering unexpected chemical structural types as active
principles under test conditions. These can then serve as
starting points for further elaboration into suitable drugs
(Burger 1982). The screening of Eucomis extracts for COX
inhibitors has revealed the great potential that this genus
shows for the discovery of COX-1 and more importantly,
selective COX-2 inhibitors.
The ratio of COX-2/COX-1 inhibitory activities for the
crude bulb and root extracts were less than one, indicating
the preferential COX-2 inhibitory activity of these extracts,
which further validates the use of these particular plants in
traditional medicine. Even though extracts prepared from
Eucomis plants, especially the crude extracts, are not high-
Figure 1: The percentage inhibition of the COX-1 / COX-2 enzymes
by bulb extracts (ethanol) of various Eucomis species. Screening
concentration for crude extracts was 250μg ml-1. Error bars repre-
sent the S.E., bars bearing different letters are significantly different,
P ≤ 0.05. Species marked with * have significantly different values
for COX-1 and COX-2 inhibition, P ≤ 0.05
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Figure 2: The % inhibition of the COX-2 enzyme by ethanol
extracts of the leaves, bulbs and roots of E. autumnalis autumnalis.
Screening concentration of the extracts was 250μg ml-1. Bars bear-
ing different letters are significantly different, P ≤ 0.05
0 10 20 30 40 50 60 70 80 90 100 110
E. autumnalis subsp
autumnalis
E. autumnalis subsp
amaryllidifo lia
E. autumnalis subsp
clavata
E. bico lor
E. comosa-comosa
E. humilis
E. comosa-punctata 
E. comosa-punctata
(striata)
E. po le-evansii
E. zambesiaca
Hybrid
S
p
e
c
ie
s
COX inhibitory activity (%)
COX-1 COX-2
e
c
b
c
b
d
a
f
b
e
a
a
ab
b
ab
c
b
c
ab
de
a
b
*
*
*
*
Table 1: IC50 values for COX inhibition by the crude ethanol
extracts from the leaves, bulbs and roots of E. autumnalis autum-
nalis
Extract IC50 values (μg ml-1) COX-2/COX-1 Ratio
COX-1 COX-2
Leaf 15 29 1.9
Bulb 72 55 0.8
Root 27 18 0.7
Indomethacin (μm) 3.1 188 61
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Figure 3: Regression analyses of the crude extracts (ethanol) pre-
pared from the leaves, bulbs and roots of E. autumnalis autumnalis,
tested in the COX-1 (n) and COX-2 (t) assays
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Figure 4: The relative inhibition of COX-1 and COX-2 enzymes by
the hexane, ethyl acetate and ethanol fractions from the serial
extraction of E. autumnalis autumnalis (A) leaves, (B) bulbs and (C)
roots. Screening concentration of extracts was 250μg ml-1. Error
bars represent the S.E.
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ly specific for COX-2 inhibition, the relatively low IC50 values
for COX-2 inhibitory activity makes these extracts valuable
medicinal preparations and emphasises the potential that
traditional remedies show for the discovery of new drugs.
These preparations, which have been utilised for centuries
as drugs, show potential pharmacological value that certain-
ly warrants further research to isolate and identify potential-
ly potent COX-1 and/or COX-2 inhibitors. This must then be
correlated with clinical trials to ensure the bioavailability of
the compounds as potential drugs.
Acknowledgements — The National Research Foundation is
thanked for their financial support of this project. The advice of Dr S
Zshocke concerning the COX assays is gratefully acknowledged.
References
Baker (1897) Eucomis L’Herit. Flora Capensis VI: 475–478
Balandrin MF, Kinghorn AD, Farnsworth NR (1993) Plant-derived
natural products in drug discovery and development. An
overview. In: Kinghorn AD, Balandrin MF (eds) Human Medicinal
Agents from Plants. ACS Symposium Series 534. American
Chemical Society, Washington, USA, pp 2–12. ISBN
0–8412–2705–5
Burger A (1982) Approaches to screening compounds for pharma-
cological activity. In: Hamner CE (ed.) Drug development. CRC
Press, Boca Raton (Florida), USA, pp 65–73. ISBN
0–8493–6310–1
Campbell WB (1990) Lipid-derived autocoids: Eicosanoids and
platelet activating factor In: Gilman AG, Rall TW, Nies AS, Taylor
P (eds) The Pharmacological Basis of Therapeutics, 8th Edn.
Pergamon Press, New York, USA, pp 600–617
Compton J (1990) Eucomis L’Heritier. Plantsman 12: 129–139
Cotton CM (1996) Ethnobotany. Principles and Applications. Wiley
and Sons, Chichester, UK, pp 242–348. ISBN 0 47195537 X
Goetzl EJ, An S, Smith WL (1995) Specificity of expression and
effects of eicosanoid mediators in normal physiology and human
diseases. FASEB 9: 1051–1058
Hinman JW (1973) Round table discussion on inflammation. In:
Kahn RH, Lands WEM (eds) Prostaglandins and Cyclic AMP.
Biological actions and clinical applications. Academic Press, New
York, USA, pp 207–210. ISBN 0–12–3944503
Hutchings A, Scott AH, Lewis G, Cunningham AB (1996) Zulu
Medicinal Plants. An Inventory. University of Natal Press, pp
42–43. ISBN 0 86980 923 7
Jäger AK, Hutchings A, Van Staden J (1996) Screening of Zulu
medicinal plants for prostaglandin-synthesis inhibitors. Journal
of  Ethnopharmacology 52: 95–100
Kamil M (1993) Biological and pharmacological implications of
flavonoids — A review. In: Govil JN, Singh VK, Hashmi S (eds)
Medicinal Plants: New vistas of research (Part 2). Today &
Tomorrow’s Printers and Publishers, New Delhi, India, pp
377–389. ISBN 1–55528–273–3
Markey CM, Alward A, Weller PE, Marnett LJ (1987) Quantitative
studies of hydroperoxide reduction by prostaglandin synthase.
Reducing substrate specificity and the relationship of peroxidase
to cyclooxygenase activities. The Journal of Biological
Chemistry 262: 6266–6279
Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, Vane
JR (1994) Selectivity of nonsteroidal anti-inflammatory drugs as
inhibitors of constitutive and inducible cyclooxygenase.
Proceedings of the National Academy of Science of the
United States of America 90: 11693–11697
Noreen Y, Ringbom T, Perera P, Danielson H, Bohlin L (1998)
Development of a radiochemical cyclooxygenase-1 and -2 in vitro
assay, for identification of natural products as inhibitors of
prostaglandin biosynthesis. Journal of Natural Products 61:
2–7
Quellet M, Percival MD (1995) Effect of inhibitor time-dependency
on selectivity towards cyclooxygenase isoforms. Biochemistry
Journal 306: 247–251
Raz A, Schwartzman M, Kenig-Wakshal R (1976) Chemical and
enzymatic transformations of prostaglandin endoperoxides:
Evidence for the predominance of the 15-hydroperoxyl pathway.
European Journal of Biochemistry 70: 89–96
Reyneke WF (1980) Three subspecies of Eucomis autumnalis.
Bothalia 13: 140–142
Roberts M (1990) Indigenous Healing Plants. Creda Press, Cape
Town, South Africa, pp 251. ISBN 1–86812–317–0
Smith JB (1990) Prostaglandins and related eicosanoids. In:
DiPalma JR, DiGregorio GJ (eds) Basic Pharmacology in
Medicine, 3rd Ed. McGraw-Hill Publ, New York, USA, pp
181–192. ISBN 0–07–017013–4
Taketo MM (1998) Cyclooxygenase-2 inhibitors in tumorigenesis
(Part I). Journal of the National Cancer Institute 90:
1529–1536
Taylor JLS, Van Staden J (2001) COX-1 inhibitory activity in extracts
from Eucomis L’Herit. Species. Journal of Ethnopharmacology
75: 257–265
Vane JR, Botting RM (1995) New insights into the mode of action of
anti-inflammatory drugs. Inflammation Research 44: 1–10
Van Wyk B-E, Van Oudtshoorn B, Gericke N (1997) Medicinal
Plants of South Africa. Briza Publications, Pretoria, South Africa,
pp 8–22, 130. ISBN 1–875093–09–5
Wallace JL, Chin BC (1997) New generation NSAIDS: The benefits
without the risks? Drugs of Today 33: 371–378
White HL, Glassman AT (1974) A simple radiochemical assay for
prostaglandin synthetase. Prostaglandins 7: 123–129
Edited by AK Jäger
South African Journal of Botany 2002, 68: 80–85
